Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating costs and expenses
General and administrative	$ 4,515	$ 1,676	$ 8,564	$ 5,231
Research and development	61	100	2,113	497
Research and development - license acquired	525	3	525	1,128
Total operating expenses	5,101	1,779	11,202	6,856
Loss from operations	(5,101)	(1,779)	(11,202)	(6,856)
Other (expenses) income
Other income			64	135
Interest income	187	40	586	107
Loss on marketable securities	(1,654)	(3,033)	(4,390)	(2,574)
Change in fair value of investments	329	4,725	91	3,827
Total other (expenses) income	(1,138)	1,732	(3,649)	1,495
Net loss	(6,239)	(47)	(14,851)	(5,361)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock			(4,109)
Net Loss Attributable to Common Shareholders	$ (6,239)	$ (47)	$ (18,960)	$ (5,361)
Net loss per share, basic and diluted
Basic and Diluted (in Dollars per share)	$ (1.17)	$ (0.01)	$ (3.59)	$ (1.14)
Weighted average number of shares outstanding, basic and diluted
Basic and Diluted (in Shares)	5,344,989	5,272,446	5,283,182	4,702,556